Scott Myslinski began his career in contract drug manufacturing in 2012 and joined Altasciences in 2014 as a Manufacturing Associate.

Screening for Pre-Existing Antibodies to Adenovirus for Nonclinical Gene Therapy Programs

Clinical trial start-up is a critical phase that carries many risks of delay, that can adversely impact the study timelines and budget. Altasciences was able to achieve an expedited project launch from the typical 12-week start-up process to just 3.5 weeks for a client by aligning our internal team on all objectives, engaging in open dialogue with the sponsor, and optimizing project management by assigning two project leads in two different time zones.

Case Study—Gene Therapy and Stem Cell Transplantation Via MRI-Guided Intraparenchymal Delivery Into Brain Regions (Cortical and Subcortical)

Case Study—Driving Simulator Assessment

Lipid Nanoparticles: A Comprehensive Assessment of Liver Enzymes and Immunopathology Markers in Nonhuman Primates

Leveraging Nonclinical Safety Evaluation Findings to Expedite Next-Generation Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) Development for Metabolic Disorders and Beyond

Subscribe to